The market has high hopes for SKB264's clinical data on NSCLC/TNBC, which will impact Akeso's future expectations. Be cautious of share price fluctuations in July due to restricted shares being lifted
What is covered in the Full Insight:
Overview of the Market Expectations for SKB264
Potential of SKB264 in Displacing Chemotherapy
Clinical Results of TROP2 ADC in NSCLC Indication
Important Clinical Trials for SKB264
Upcoming Lifting of Restricted Shares
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.